Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website

DVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1778 of 1780  at  9/27/2020 1:13:00 PM  by

fairvalueforyou


 In response to msg 1777 by  warlord_2010
view thread

Re: Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study

Clover's covid19 vaccine failed to fully protect Rhesus macaques as its new release indicated as "significant reduction in viral loads in lung tissues and swbs". It is not as good as Chinese SinoVac inactive covid19 vaccine NHP challenge data which fully protect NHP without viral detected.
Comparing to NVAX 2373 NHP challenge data, it is not even close
----------------------------------------------------------------------------------------------------------
 
Clover’s COVID-19 S-Trimer vaccine was developed by combining the trimeric SARS-CoV-2 spike (S)-protein with the company’s proprietary Trimer-Tag© technology. In preclinical studies, adjuvanted S-Trimer induced strong humoral and Th1-biased cell-mediated immune responses in mice, rats and monkeys, with levels of neutralizing antibodies at or higher than levels observed in human convalescent sera. Rhesus macaques that received the vaccine and were subsequently challenged with SARS-CoV-2 virus were protected against infection, as demonstrated by clinical observations (protection from body weight loss and increases in body temperature) and significant reduction in viral loads in lung tissues and swabs, with no signs of disease enhancement. Strong immune responses and protection were observed when the S-Trimer was administered with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 adjuvant plus alum. These positive preclinical data supported the decision to progress adjuvanted vaccine candidates using both adjuvants into Clover’s ongoing Phase 1 clinical study of S-Trimer in healthy adult and elderly participants.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 119
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1779 Re: Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study LookoutJoe 1 9/27/2020 7:57:17 PM






Financial Market Data provided by
.
Loading...